Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06654219

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia

The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ultrasound assessment and volume of gastric contents visualized on upper endoscopy, to determine time of gastric emptying by serial Gastric ultrasonography (GUS) scans every 2 hours in subjects who presented with an initial at-risk scan, to determine the choice of anesthesia used based on preoperative GUS results, to determine if there were any adverse events recorded in this study group, to determine if duration of GLP-1 RA therapy has an association with residual gastric content (RGC). and to determine if dosing of GLP-1 RA has an association with RGC.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists
  • Undergoing upper endoscopy only - no colonoscopy due to prep

Exclusion criteria

  • Previous gastric resection or bypass
  • Gastric band in situ
  • Previous fundoplication
  • Large hiatal hernia
  • Pregnant patients
  • Recent trauma
  • Inability to turn to the right lateral decubitus position.
  • Patients on erythromycin, metoclopramide, domperidone, opioids.
  • Gastroparesis previous

Treatment and study plan

GLP-1 RA users with prolonged fasting instructions

Other

NPO for solids: 24 hours prior to procedure, clear liquid diet (CLD) for 24 hours with last intake of clears no less than 2 hours prior to a procedure.GLP-1 RA will not be held prior to surgery and usual dosing schedule will be followed prior to procedure.

GLP-1 RA users with standard NPO instructions

Other

NPO after midnight prior to procedure; Minimum solid fasting duration of 8 hours for solids and 2 hours for liquids. Last dose of GLP-1 RA no less than 7 days prior to procedure.

Primary outcomes

  1. Number of participants that show prevalence of increased RGC determined using preoperative GUS

    Time frame: prior to procedure ( within 2 hours before procedure)

    Participants with increased RGC will have solids, thick fluid, or clear fluids >1.5ml/kg in the gastric antrum in the right lateral decubitus position

Secondary outcomes

  1. Number of participants that show thirst as assessed by the VAS

    Time frame: prior to procedure ( within 2 hours before procedure)

    This is measured in a linear scale from 1-10, higher number showing worse outcome

  2. Number of participants that show hunger as assessed by the VAS

    Time frame: prior to procedure ( within 2 hours before procedure)

    This is measured in a linear scale from 1-10, higher number showing worse outcome

  3. Number of participants that show anxiety as assessed by the VAS

    Time frame: prior to procedure ( within 2 hours before procedure)

    This is measured in a linear scale from 1-10, higher number showing worse outcome

Study contacts

Contact information is provided by the study sponsor or research team.

Paul Potnuru

CONTACT

[email protected]

(713) 500-6271

Sudipta Sen, MD, FASA

CONTACT

[email protected]

(713) 500-6202

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Registry information

Official study title

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor Agonist Prior to Anesthesia

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 23, 2024
Registry last updated
Nov 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.